0.81
-0.0246(-2.96%)
Currency In USD
| Previous Close | 0.83 |
| Open | 0.85 |
| Day High | 0.85 |
| Day Low | 0.77 |
| 52-Week High | 1.7 |
| 52-Week Low | 0.62 |
| Volume | 1.89M |
| Average Volume | 724,275 |
| Market Cap | 41.83M |
| PE | -1.15 |
| EPS | -0.7 |
| Moving Average 50 Days | 0.78 |
| Moving Average 200 Days | 0.77 |
| Change | -0.02 |
If you invested $1000 in Xilio Therapeutics, Inc. (XLO) since IPO date, it would be worth $50.44 as of November 09, 2025 at a share price of $0.807. Whereas If you bought $1000 worth of Xilio Therapeutics, Inc. (XLO) shares 3 years ago, it would be worth $352.4 as of November 09, 2025 at a share price of $0.807.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Nov 07, 2025 2:05 PM GMT
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Co
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Nov 07, 2025 2:01 PM GMT
Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindode
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
GlobeNewswire Inc.
Oct 30, 2025 1:01 PM GMT
WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced tha